The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Summary

The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.

Timeline

Start

2019-07

Primary completion

2022-04

Completion

2023-05

Outcome

Outcome not reported

Stopped: “Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.”

Drugs

Indications